LUMINOUS study sheds light on AMD patient characteristics


Dermot McGrath
Published: Friday, September 8, 2017
Baseline patient data from the largest-ever study conducted in medical retina should help to shed valuable light on the use of ranibizumab in a daily clinical setting, according to Christopher Brand MD at the 17th EURETINA Congress in Barcelona.
“The data from the LUMINOUS study will provide long-term evidence on the use of ranibizumab in the real-world setting, and may guide physicians in making treatment decisions to optimise patient outcomes with ranibizumab treatment,” said Dr Brand.
The five-year prospective LUMINOUS study enrolled more than 30,000 patients from 494 sites across 43 countries, and was designed to evaluate the long-term effectiveness, safety and treatment patterns associated with ranibizumab treatment in patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularisation (mCNV) in real-world setting.
“One of the real values of a study of this size is that it included patients from routine clinical practice with more diverse demographics, ocular baseline characteristics and co-morbidities than usual randomised controlled trials in which difficult to treat patients are excluded,” he said.
The data from the LUMINOUS study will help to provide long-term evidence on the use of ranibizumab in the real-world setting and may guide physicians in making treatment decisions to optimise patient outcomes with ranibizumab treatment.
“This will hopefully improve vision and quality of life for our patients,” he concluded.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.